Adjuvant high-dose chemotherapy (HDC) with autologous hematopoietic stem-cell transplantation (AHST) for high-risk primary breast cancer has not been shown to prolong survival. Individual trials have had limited power to show overall benefit or benefits within subsets
High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer : overview of 15 randomized trials / D.A. Berry, N.T. Ueno, M.M. Johnson, X. Lei, J. Caputo, S. Rodenhuis, W.P. Peters, R.C. Leonard, W.E. Barlow, M.S. Tallman, J. Bergh, U.A. Nitz, A. Gianni, R.L. Basser, A.R. Zander, R.C. Coombes, H. Roché, Y. Tokuda, E.G. De Vries, G.N. Hortobagyi, J.P. Crown, P. Pedrazzoli, M. Bregni, T. Demirer. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 29:24(2011 Aug 20), pp. 3214-3223.
High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer : overview of 15 randomized trials
A. Gianni;
2011
Abstract
Adjuvant high-dose chemotherapy (HDC) with autologous hematopoietic stem-cell transplantation (AHST) for high-risk primary breast cancer has not been shown to prolong survival. Individual trials have had limited power to show overall benefit or benefits within subsets
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
